← Back to all trials
Not Yet Recruiting
NCT07710781
Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic Malignancies
Conditions: Hematologic Malignancy, Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Biphenotypic Leukemia, Acute Undifferentiated Leukemia, CLL (Chronic Lymphocytic Leukemia), Chronic Myeloid Leukemia, MDS (Myelodysplastic Syndrome), Non Hodgkin Lymphoma, Hodgkin Lymphoma, Cutaneous T Cell Lymphomas (CTCL)
Sex: All
Ages: 12 Years – 75 Years
Healthy volunteers: No
Phase: NA
Enrollment: 300
Sponsor: Ossium Health, Inc.
Summary
Prospective, multi-center open label study of HLA-partially to fully matched allogeneic cryopreserved deceased donor bone marrow transplantation and living donor transplantation for patients with hematologic malignancies.
Eligibility Criteria
Inclusion Criteria:
1. Patient has the ability to provide informed consent according to the applicable regulatory and local institutional requirements.
2. Male or female, aged ≥12 and ≤65 years for patients receiving MAC aged ≥12 and ≤75 years for patients receiving RIC. Patients between 75 and 80 years on RIC regimen can be enrolled with prior sponsor approval
3. Patient must require first allogeneic HCT per the discretion of the treating physician
4. BMI \
Source: ClinicalTrials.gov (NCT07710781). StuddyBuddy aggregates publicly available trial information.
